Swiss drugmaker Novartis AG (NVS, Financial) in April reported first-quarter 2012 earnings per share (EPS) of $1.27, down from the $1.4 posted a year earlier. First-quarter revenue fell to $13.7 billion from last year’s $14 billion. Earnings dropped 18 percent, to $2.3 billion.
Novartis’ revenue was hit by generic drug competition and manufacturing problems at its factory in Lincoln, Nebraska. This year, Novartis faces additionĂ‚Âal challenges to revenue, as its top-selling drug Diovan for hypertension loses patent protection.
However, the company isn’t taking patent protection lying down. Its recent $50 billion acquisition of Alcon (ACL, Financial), a developer of eye-care products, as well as the launch of new drugs, will help offset any patent losses. The comĂ‚Âpany expects 2012 revenue to be roughly in line with 2011.
Novartis’ portfolio contains plenty of proven, big-selling drugs. The compaĂ‚Âny’s sales of Afinitor, for the treatment of advanced kidney cancer, leaped 60 percent in the first quarter to $143 million; sales of the chronic leukemia drug Tasigna jumped 39 percent to $209 million; and sales of eye drug Lucentis inĂ‚Âcreased 30 percent to $567 million. Moreover, the company’s Gilenya, the first oral treatment approved for multiple sclerosis, continues to capture market share and generated sales of $247 million during the period.
Novartis’ Alcon unit also performed well, racking up a 5 percent increase in revenue to $2.5 billion. On the downside, the company’s Consumer Health segment endured a 20 percent drop in first-quarter sales to $932 million, stemming from the suspension of its troubled Lincoln manufacturing site. However, the company has now resolved these glitches and expects to resume full-throttle production by mid-year.
Novartis continues to funnel substantial resources into developing new prodĂ‚Âuct lines. The company spent $9.6 billion in research and development (R&D) last year, about 16.4 percent of revenue. This R&D commitment is paying off with a deep bench of potentially profitable products. The company recently anĂ‚Ânounced plans to make regulatory filings for more than 60 new drug treatments through 2015.
Novartis also reached an agreement to acquire the Chinese vaccines compaĂ‚Âny Zhejiang Tianyuan Bio-Pharmaceutical Co, as part of a strategic push into the fast-growing and potentially vast vaccine market in China.
In addition to its growth prospects, Novartis sports an attractive dividend yield of 4.49 percent. The company’s earnings yield is around 7 percent, which means it pays out nearly 65 percent of earnings as dividends
Novartis’ revenue was hit by generic drug competition and manufacturing problems at its factory in Lincoln, Nebraska. This year, Novartis faces additionĂ‚Âal challenges to revenue, as its top-selling drug Diovan for hypertension loses patent protection.
However, the company isn’t taking patent protection lying down. Its recent $50 billion acquisition of Alcon (ACL, Financial), a developer of eye-care products, as well as the launch of new drugs, will help offset any patent losses. The comĂ‚Âpany expects 2012 revenue to be roughly in line with 2011.
Novartis’ portfolio contains plenty of proven, big-selling drugs. The compaĂ‚Âny’s sales of Afinitor, for the treatment of advanced kidney cancer, leaped 60 percent in the first quarter to $143 million; sales of the chronic leukemia drug Tasigna jumped 39 percent to $209 million; and sales of eye drug Lucentis inĂ‚Âcreased 30 percent to $567 million. Moreover, the company’s Gilenya, the first oral treatment approved for multiple sclerosis, continues to capture market share and generated sales of $247 million during the period.
Novartis’ Alcon unit also performed well, racking up a 5 percent increase in revenue to $2.5 billion. On the downside, the company’s Consumer Health segment endured a 20 percent drop in first-quarter sales to $932 million, stemming from the suspension of its troubled Lincoln manufacturing site. However, the company has now resolved these glitches and expects to resume full-throttle production by mid-year.
Novartis continues to funnel substantial resources into developing new prodĂ‚Âuct lines. The company spent $9.6 billion in research and development (R&D) last year, about 16.4 percent of revenue. This R&D commitment is paying off with a deep bench of potentially profitable products. The company recently anĂ‚Ânounced plans to make regulatory filings for more than 60 new drug treatments through 2015.
Novartis also reached an agreement to acquire the Chinese vaccines compaĂ‚Âny Zhejiang Tianyuan Bio-Pharmaceutical Co, as part of a strategic push into the fast-growing and potentially vast vaccine market in China.
In addition to its growth prospects, Novartis sports an attractive dividend yield of 4.49 percent. The company’s earnings yield is around 7 percent, which means it pays out nearly 65 percent of earnings as dividends
